Dermata Therapeutics reported a second-quarter 2026 net loss of $2.97 million, or $0.74 per diluted share, as it prepares to launch its first direct-to-consumer skincare product. The loss widened from $1.70 million, or $1.66 per diluted share, in the same period last year, while operating expenses rose to $3.0 million from $1.8 million, driven by higher legal, marketing, and commercialization costs. The company plans to launch Tome Foundational Treatment, a once-weekly skin renewal therapy, on August 25, 2026, marking its transition into a commercial-stage skincare company. Cash and cash equivalents stood at $4.4 million at quarter-end, which management expects to fund operations into the fourth quarter of 2026. Dermata is also advancing a second product, a topical acne treatment, to follow the initial launch.
Dermata Therapeutics IncQ2 2026 net loss widened to $2.97M and cash only funds operations into Q4 2026.
